Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Stem Cell & Islet Transplant Reverses Type 1 Diabetes in Preclinical Study
Stanford researchers developed a stem cell and islet transplant strategy that successfully reverses Type 1 Diabetes in mice without immunosuppressive drugs.
Panthera Biopartners Acquires Hungarian Clinical Research Site OEC
UK-based Panthera Biopartners expands into mainland Europe by acquiring OEC, Hungary’s leading independent clinical research site network.
Isomorphic Labs Launches Human Trials for AI-Designed Cancer Drugs
Alphabet's Isomorphic Labs is beginning human clinical trials for AI-designed oncology drugs, leveraging its AlphaFold technology and $600M in funding.
Novartis' Itvisma Gene Therapy Gains CHMP Nod for SMA in Europe
The CHMP has recommended Novartis' gene therapy Itvisma for spinal muscular atrophy in Europe, offering a new treatment option following FDA approval.
Tonix Pharmaceuticals Presents Preclinical Immuno-Oncology Data at AACR
Tonix Pharmaceuticals shared updates on preclinical immuno-oncology candidates TNX-1700 and TNX-4700 at the AACR Annual Meeting 2026 in San Diego.
Study Identifies Novel Genetic Pathways Driving Cardiometabolic Diseases
A University of Oklahoma study identified two new genetic pathways linked to lipid metabolites that influence the risk of heart disease and diabetes.
CLINUVEL Receives Final EMA Scientific Advice for Phase III Vitiligo Trial
CLINUVEL announced final EMA scientific advice for the Phase III CUV107 study evaluating SCENESSE as a systemic treatment for non-segmental vitiligo.
Grace Therapeutics Receives FDA Complete Response Letter for GTx-104 NDA
The FDA issued a Complete Response Letter to Grace Therapeutics regarding the NDA for GTx-104, an investigational treatment for subarachnoid hemorrhage.
ASO Therapy Reverses Rare Neurodevelopmental Disorder Preclinical Model
St. Jude scientists reversed HNRNPH2-related neurodevelopmental disorder effects using antisense oligonucleotides in preclinical models, paving the way for trials.
FDA Grants Fast Track to BBO-11818 for Advanced KRAS-Mutant Pancreatic
BridgeBio Oncology Therapeutics receives FDA Fast Track designation for pan-KRAS inhibitor BBO-11818 for advanced KRAS-mutant pancreatic ductal adenocarcinoma.
Trevi Therapeutics Announces Closing of $173M Underwritten Public Offer
Trevi Therapeutics closes a $173 million underwritten public offering, accelerating the development of Haduvio for chronic cough and pulmonary fibrosis.
RM-055 Highlights Deep Antitumor Activity in Preclinical Cancer Models
Revolution Medicines presents preclinical data on RM-055, a mutant-targeted catalytic RAS(ON) inhibitor overcoming resistance in multiple cancer models.
1
2
3
4
5
6
7
8
